Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging reliance on A1c for diabetes management.

Motorola Solutions (MSI) accelerated its sell-off last week after falling by 5.85% on Oct. 31. Shares peaked at $507.82 in the year and closed at $406.71. The company posted a 7.5% Y/Y rise in revenue ...

The world's largest online retailer got a lift from its booming cloud computing business on Friday, Oct. 31, 2025, while a ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

After dealing with a deployment issue with glucose monitors earlier this year, interim CEO Jake Leach said improving customer ...

Dexcom shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.mo ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

What Amazon learned when it automated the creation of product pages. by Stefan Thomke, Philipp Eisenhauer and Puneet Sahni For all the enthusiasm around generative AI, there’s a hurdle that is ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.